Trinity College Dublin
|As first author||2|
|As last author||8|
G Jane Farrar(52)
Marian M Humphries(31)
Lawrence C S Tam(11)
Oliviero L Gobbo(4)
Sarah L Doyle(3)
Catherine M Greene(2)
... and 19 others
These arethe6 unique sources for Paul F Kenna's 62 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.
|Ireland -> Royal College of Surgeons in Ireland||2|
|Ireland -> Royal College of Surgeons in Ireland -> PubMed||2|
|Ireland -> Trinity College Dublin||59|
|Ireland -> Trinity College Dublin -> PubMed||43|
|Ireland -> University College Dublin||1|
|Ireland -> University College Dublin -> PubMed||1|
The present invention relates to classical pathway complement proteins and their use in the prognosis and prevention of diseases involving cone photoreceptor degeneration. Specifically, the present invention is directed to the use of one or more classical pathway complement proteins, preferably involved in the recognition phase, in the maintenance of cone photoreceptor cell viability in a degenerating retina. The invention is also directed to a method for determining the susceptibility, risk of development and/or progression of diseases involving cone photoreceptor degeneration in a subject.
The invention relates to gene suppression and replacement. In particular, the invention relates to enhanced expression of suppression agents for suppressing gene expression in a cell and in vivo and replacement nucleic acids that are not inhibited by the suppression agent. Regulatory elements are included in expression vectors to optimize expression of the suppression agent and/or replacement nucleic acid.
The invention relates to treatment for an autosomal dominant disease of the eye such as retinitis pigmentosa or glaucoma comprising means to substantially suppress all alleles of a gene associated with the disease. Replacement of the gene is specifically disclaimed. Typically, the disease is a dominant hereditary disease in which the therapy involves suppressing both a diseased and a normal allele of the gene. The means for suppressing both alleles of the gene of interest typically comprises an siRNA molecule which is designed to silence both alleles of the gene of interest. Medicaments and kits for treating diseases are also described.
Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.
Here is a quick breakdown of this expert's publication history
If this is the expert you have been looking for, simply click here to make contact.